The stock of Apellis Pharmaceuticals Inc (APLS) has gone up by 3.00% for the week, with a 3.46% rise in the past month and a 56.63% rise in the past quarter. The volatility ratio for the week is 4.87%, and the volatility levels for the past 30 days are 5.47% for APLS. The simple moving average for the past 20 days is 2.32% for APLS’s stock, with a -20.59% simple moving average for the past 200 days.

Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?

and a 36-month beta value of 0.92. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”

The average price predicted for Apellis Pharmaceuticals Inc (APLS) by analysts is $71.19, which is $22.79 above the current market price. The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares.

APLS) stock’s latest price update

Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14. Nevertheless, the company has seen a 3.00% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

Analysts’ Opinion of APLS

Many brokerage firms have already submitted their reports for APLS stocks, with Goldman repeating the rating for APLS by listing it as a “Buy.” The predicted price for APLS in the upcoming period, according to Goldman is $74 based on the research report published on November 09, 2023 of the current year 2023.

APLS Trading at 8.11% from the 50-Day Moving Average

After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.92% of loss for the given period.

Volatility was left at 5.47%, however, over the last 30 days, the volatility rate increased by 4.87%, as shares surge +5.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.22% upper at present.

During the last 5 trading sessions, APLS rose by +3.00%, which changed the moving average for the period of 200-days by -8.21% in comparison to the 20-day moving average, which settled at $47.42. In addition, Apellis Pharmaceuticals Inc saw -6.40% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at APLS starting from Deschatelets Pascal, who sale 12,000 shares at the price of $47.27 back on Nov 08. After this action, Deschatelets Pascal now owns 1,071,807 shares of Apellis Pharmaceuticals Inc, valued at $567,240 using the latest closing price.

Chopas James George, the VP/Chief Accounting Officer of Apellis Pharmaceuticals Inc, sale 132 shares at $46.04 during a trade that took place back on Oct 23, which means that Chopas James George is holding 32,680 shares at $6,077 based on the most recent closing price.

Stock Fundamentals for APLS

Current profitability levels for the company are sitting at:

The net margin for Apellis Pharmaceuticals Inc stands at -864.70. The total capital return value is set at -171.99, while invested capital returns managed to touch -191.33. Equity return is now at value -224.59, with -71.67 for asset returns.

Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 66.35 points at debt to equity in total, while total debt to capital is 39.89. Total debt to assets is 14.83, with long-term debt to equity ratio resting at 63.04. Finally, the long-term debt to capital ratio is 37.90.

When we switch over and look at the enterprise to sales, we see a ratio of 19.29, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 8.46 and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.29.


To sum up, Apellis Pharmaceuticals Inc (APLS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.